SEC Form 4 · accession 0000899866-19-000050
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Indrani Lall Franchini
Officer — EVP, Chief Compliance Officer
Period of report
Feb 28, 2019
Accepted (ET)
Mar 5, 2019 · 8:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Feb 28, 2019 | A | 8,250 | $0.00 | A | 35,531 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date.